SG Americas Securities LLC Sells 223,368 Shares of Compass Therapeutics, Inc. $CMPX

SG Americas Securities LLC lessened its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 59.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 149,313 shares of the company’s stock after selling 223,368 shares during the period. SG Americas Securities LLC’s holdings in Compass Therapeutics were worth $523,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Apollon Wealth Management LLC acquired a new position in Compass Therapeutics in the 3rd quarter valued at $35,000. Marex Group plc bought a new position in Compass Therapeutics during the second quarter worth about $61,000. Adage Capital Partners GP L.L.C. increased its position in Compass Therapeutics by 11.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after acquiring an additional 449,868 shares during the period. Vivo Capital LLC raised its stake in Compass Therapeutics by 70.0% in the 2nd quarter. Vivo Capital LLC now owns 6,043,466 shares of the company’s stock worth $15,713,000 after purchasing an additional 2,487,443 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in Compass Therapeutics by 58.1% in the 2nd quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock valued at $153,000 after purchasing an additional 21,578 shares during the period. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Trading Down 5.9%

Shares of Compass Therapeutics stock opened at $5.90 on Friday. The firm has a market capitalization of $1.05 billion, a PE ratio of -13.11 and a beta of 1.45. The firm’s 50 day moving average is $5.31 and its 200 day moving average is $4.14. Compass Therapeutics, Inc. has a 1 year low of $1.33 and a 1 year high of $6.40.

Compass Therapeutics (NASDAQ:CMPX) last issued its earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. As a group, research analysts anticipate that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Compass Point set a $10.00 price target on shares of Compass Therapeutics in a research report on Monday, October 6th. Cantor Fitzgerald assumed coverage on Compass Therapeutics in a report on Wednesday, December 3rd. They issued an “overweight” rating for the company. Leerink Partners upgraded Compass Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 26th. Citizens Jmp began coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They issued a “market outperform” rating and a $10.00 price target for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $30.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, January 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.23.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.